NASDAQ · SIGA
Healthcare · Drug Manufacturers - Specialty & Generic
$3.29
Down-$0.03 (-0.91%)
Updated Oct 7, 2026, 10:01 PM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SIGA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
SIGA closed at $3.29 after 21 trading sessions, up 2.81% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $3.48 | $3.485 | $3.23 | $3.29 | 795.04K |
| Oct 5, 2026 | $3.40 | $3.675 | $3.40 | $3.48 | 964.03K |
| Oct 2, 2026 | $3.40 | $3.43 | $3.285 | $3.38 | 642.04K |
| Oct 1, 2026 | $3.41 | $3.44 | $3.31 | $3.35 | 619.93K |
| Sep 30, 2026 | $3.44 | $3.44 | $3.345 | $3.40 | 661.39K |
| Sep 29, 2026 | $3.48 | $3.485 | $3.35 | $3.44 | 439.96K |
| Sep 28, 2026 | $3.43 | $3.50 | $3.335 | $3.46 | 645.56K |
| Sep 25, 2026 | $3.26 | $3.52 | $3.225 | $3.45 | 1.17M |
| Sep 24, 2026 | $3.17 | $3.27 | $3.15 | $3.25 | 1.12M |
| Sep 23, 2026 | $3.25 | $3.27 | $3.13 | $3.17 | 435.19K |
| Sep 22, 2026 | $3.19 | $3.305 | $3.15 | $3.26 | 493.6K |
| Sep 21, 2026 | $3.13 | $3.17 | $3.08 | $3.16 | 471.19K |
| Sep 18, 2026 | $3.03 | $3.20 | $3.005 | $3.14 | 746.25K |
| Sep 17, 2026 | $3.09 | $3.1251 | $3.04 | $3.05 | 711.06K |
| Sep 16, 2026 | $2.98 | $3.10 | $2.93 | $3.10 | 811.87K |
| Sep 15, 2026 | $3.14 | $3.14 | $2.935 | $2.98 | 480.09K |
| Sep 14, 2026 | $3.04 | $3.155 | $2.9904 | $3.15 | 522.91K |
| Sep 11, 2026 | $3.06 | $3.0817 | $3.01 | $3.03 | 453.37K |
| Sep 10, 2026 | $3.07 | $3.07 | $3.00 | $3.02 | 550.42K |
| Sep 9, 2026 | $3.20 | $3.25 | $3.04 | $3.08 | 582.77K |
| Sep 8, 2026 | $3.245 | $3.275 | $3.14 | $3.20 | 786.13K |
The latest Smart Investors Daily articles mentioning SIGA.
Company
Market Activity
Research & News
SIGA research
Company profile and research snapshot.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Sep 6, 2026
On August 6, SIGA Technologies (NASDAQ:SIGA) reported financial results for the three and six months ended June 30, and the numbers tell two very different stories depending on which quarter you compare them to. Revenue and profit both cratered from a year ago, yet the company still turned a profit, paid out a special dividend, […]
SeekingAlpha · Sep 1, 2026
SIGA Technologies (SIGA) stock analysis: BARDA TPOXX contract nearing exhaustion, renewal uncertain. Read here for a detailed investment analysis.
Benzinga · Aug 7, 2026
https://www.cdc.gov/measles/data-research/index.html
SeekingAlpha · Aug 7, 2026
SIGA Technologies, Inc. (SIGA) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsDiem Nguyen - CEO & DirectorDaniel Luckshire -...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SIGA.
